Home » Early VAP & CP

Thought Leadership

We work to understand ways in which our practice areas, Value, Access, and Pricing (VAP) and Commercial Planning (CP), intersect and influence each other in the early pipeline stages.

Showing 1 of 1 posts
Novel Combinations Double the Trouble
May 25, 2021 | Blogs

Novel Combinations: Double the Trouble

Launching a novel combination therapy provides a unique set of challenges and opportunities when seeking to achieve positive pricing and access outcomes. In this article, CBPartners reviewed the pricing and access outcomes from prior novel immuno-oncology combinations and have developed considerations for manufacturers developing strategies for their future pipeline.